PeterAndrewRiedellMD

Oncology • Chicago, IL

Hematologic Oncology

Associate Professor

Join to view full profile

Dr. Riedell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Riedell's full profile

Already have an account?

Office
5841 S. MARYLAND
M/C 2115
Chicago, IL 60637
Phone+1 773-702-8412

Fax+1 773-834-0188

Summary

Dr. Peter Riedell is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. He received his medical degree from University of Tennessee College of Medicine and has been in practice 7 years. He specializes in hematologic oncology and is experienced in non-Hodgkin lymphoma, Hodgkin lymphoma, stem cell transplantation, and chimeric antigen receptor (CAR) T-cell therapy.

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2013 - 2016
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2010 - 2013
University of Tennessee Health Science Center College of MedicineClass of 2010

Certifications & Licensure

IL State Medical License 2016 - 2026
MO State Medical License 2012 - 2017
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Start of enrollment: 2015 Feb 04
Completed
Phase 1
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2016 Oct 12
Active, not recruiting
Phase 3
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Start of enrollment: 2018 Mar 06
Recruiting
Phase 3
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
Recruiting
Phase 1, Phase 2
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2018 Jan 25
Active, not recruiting
Phase 3
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma Start of enrollment: 2018 Nov 12
Active, not recruiting
Phase 2
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients Start of enrollment: 2018 Oct 09
Completed
Phase 1
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma Start of enrollment: 2019 Jan 29
Completed
Phase 2
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma Start of enrollment: 2019 Nov 05
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Establishing meaningful change thresholds for European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire CLL-specific module domain score...
Laurie Eliason, Fatoumata Fofana, Lin Wang, Peter A Riedell, Shien Guo
Ejhaem. 2024-12-01
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Gregory W Roloff, Satyajit Kosuri, Mariam T Nawas, Adam S DuVall, Anand A Patel
Haematologica. 2024-11-01
Correction to: Moving T‑Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review.
Nathan Hale Fowler, Julio C Chavez, Peter A Riedell
Targeted Oncology. 2024-09-01

Abstracts/Posters

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas
Peter A. Riedell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisoc...
Peter A. Riedell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients...
Peter A. Riedell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
Peter A. Riedell, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/8/2019
Join now to see all

Lectures

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecl...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Axi-Cel vs Tisa-Cel in the Real World: Patterns of Use, Efficacy, and Safety in B-cell LymphomaApril 22nd, 2020
Experts Break down Latest CAR T-cell Advances in LymphomaJanuary 22nd, 2020
Triplet Notches Survival Win in Heavily Pretreated DLBCLJune 3rd, 2024
Join now to see all